Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Spyre Therapeutics Inc (SYRE)

Spyre Therapeutics Inc (SYRE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Spyre Therapeutics Inc 221 CRESCENT STREET BUILDING 23 SUITE 105 WALTHAM MA 02453 USA

www.spyre.com Employees: 65 P: 617-651-5940

Sector:

Medical

Description:

Spyre Therapeutics is a biotechnology company which aims to create inflammatory bowel disease products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches for patient selection. Spyre Therapeutics, formerly known as Aeglea BioTherapeutics Inc., is based in WALTHAM, Mass.

Key Statistics

Overview:

Market Capitalization, $K 2,595,453
Enterprise Value, $K 2,661,853
Shares Outstanding, K 77,592
Annual Sales, $ 0 K
Annual Net Income, $ -208,020 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -11,180 K
EBIT, $ -213,650 K
EBITDA, $ -225,050 K
60-Month Beta 3.14
% of Insider Shareholders 15.43%
% of Institutional Shareholders 80.39%
Float, K 65,620
% Float 84.57%
Short Volume Ratio 0.71

Growth:

1-Year Return 28.16%
3-Year Return 255.66%
5-Year Return -84.31%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 94.81%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.15 on 11/04/25
Next Earnings Date 11/06/25
Earnings Per Share ttm -2.19
EPS Growth vs. Prev Qtr 69.39%
EPS Growth vs. Prev Year 88.97%
Annual Dividend & Yield 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-25 on 09/08/23

SYRE Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -46.26%
Return-on-Assets % -26.82%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 8.69
Book Value/Share 5.87
Interest Coverage -3.54
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar